I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the ...

Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate in the field ... observe that the safety and PK profile that had been generated from ...

Effects on clinical parameters including days with lesions ... into Phase 1b studies after each long-acting helicase-primase inhibitor candidate exceeded the company’s target PK profiles in Phase 1a ...